Multi-HLA class II tetramer analyses of citrulline-reactive T cells and early treatment response in rheumatoid arthritis.
Adult
Aged
Arthritis, Rheumatoid
/ drug therapy
CD4-Positive T-Lymphocytes
/ drug effects
Citrulline
/ therapeutic use
Epitopes, T-Lymphocyte
/ drug effects
Extracellular Matrix Proteins
/ metabolism
Female
Fibrinogen
/ metabolism
Flow Cytometry
/ methods
Histocompatibility Antigens Class II
/ metabolism
Humans
Male
Middle Aged
Pyrophosphatases
/ metabolism
Vimentin
/ therapeutic use
Autoimmune disease
Autoreactive CD4+ T lymphocytes
Citrullination
Multi-MHC class II tetramer assay
Journal
BMC immunology
ISSN: 1471-2172
Titre abrégé: BMC Immunol
Pays: England
ID NLM: 100966980
Informations de publication
Date de publication:
18 05 2020
18 05 2020
Historique:
received:
16
08
2019
accepted:
04
05
2020
entrez:
20
5
2020
pubmed:
20
5
2020
medline:
5
6
2021
Statut:
epublish
Résumé
HLA class II tetramers can be used for ex vivo enumeration and phenotypic characterisation of antigen-specific CD4+ T cells. They are increasingly applied in settings like allergy, vaccination and autoimmune diseases. Rheumatoid arthritis (RA) is a chronic autoimmune disorder for which many autoantigens have been described. Using multi-parameter flow cytometry, we developed a multi-HLA class II tetramer approach to simultaneously study several antigen specificities in RA patient samples. We focused on previously described citrullinated HLA-DRB1*04:01-restricted T cell epitopes from α-enolase, fibrinogen-β, vimentin as well as cartilage intermediate layer protein (CILP). First, we examined inter-assay variability and the sensitivity of the assay in peripheral blood from healthy donors (n = 7). Next, we confirmed the robustness and sensitivity in a cohort of RA patients with repeat blood draws (n = 14). We then applied our method in two different settings. We assessed lymphoid tissue from seropositive arthralgia (n = 5) and early RA patients (n = 5) and could demonstrate autoreactive T cells in individuals at risk of developing RA. Lastly, we studied peripheral blood from early RA patients (n = 10) and found that the group of patients achieving minimum disease activity (DAS28 < 2.6) at 6 months follow-up displayed a decrease in the frequency of citrulline-specific T cells. Our study demonstrates the development of a sensitive tetramer panel allowing simultaneous characterisation of antigen-specific T cells in ex vivo patient samples including RA 'at risk' subjects. This multi-tetramer approach can be useful for longitudinal immune-monitoring in any disease with known HLA-restriction element and several candidate antigens.
Sections du résumé
BACKGROUND
HLA class II tetramers can be used for ex vivo enumeration and phenotypic characterisation of antigen-specific CD4+ T cells. They are increasingly applied in settings like allergy, vaccination and autoimmune diseases. Rheumatoid arthritis (RA) is a chronic autoimmune disorder for which many autoantigens have been described.
RESULTS
Using multi-parameter flow cytometry, we developed a multi-HLA class II tetramer approach to simultaneously study several antigen specificities in RA patient samples. We focused on previously described citrullinated HLA-DRB1*04:01-restricted T cell epitopes from α-enolase, fibrinogen-β, vimentin as well as cartilage intermediate layer protein (CILP). First, we examined inter-assay variability and the sensitivity of the assay in peripheral blood from healthy donors (n = 7). Next, we confirmed the robustness and sensitivity in a cohort of RA patients with repeat blood draws (n = 14). We then applied our method in two different settings. We assessed lymphoid tissue from seropositive arthralgia (n = 5) and early RA patients (n = 5) and could demonstrate autoreactive T cells in individuals at risk of developing RA. Lastly, we studied peripheral blood from early RA patients (n = 10) and found that the group of patients achieving minimum disease activity (DAS28 < 2.6) at 6 months follow-up displayed a decrease in the frequency of citrulline-specific T cells.
CONCLUSIONS
Our study demonstrates the development of a sensitive tetramer panel allowing simultaneous characterisation of antigen-specific T cells in ex vivo patient samples including RA 'at risk' subjects. This multi-tetramer approach can be useful for longitudinal immune-monitoring in any disease with known HLA-restriction element and several candidate antigens.
Identifiants
pubmed: 32423478
doi: 10.1186/s12865-020-00357-w
pii: 10.1186/s12865-020-00357-w
pmc: PMC7236297
doi:
Substances chimiques
Epitopes, T-Lymphocyte
0
Extracellular Matrix Proteins
0
Histocompatibility Antigens Class II
0
Vimentin
0
Citrulline
29VT07BGDA
Fibrinogen
9001-32-5
Pyrophosphatases
EC 3.6.1.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
27Subventions
Organisme : Reumatikerförbundet
ID : R-481771
Pays : International
Organisme : Stiftelsen Konung Gustaf V:s 80-årsfond
ID : FAI-2016-0312
Pays : International
Organisme : Stiftelsen Konung Gustaf V:s 80-årsfond
ID : FAI-2016-0312
Pays : International
Organisme : Vetenskapsrådet
ID : 2015-02900
Pays : International
Organisme : Innovative Medicines Initiative
ID : BTCure 115142
Pays : International
Organisme : Innovative Medicines Initiative
ID : RTCure 777357
Pays : International
Organisme : Innovative Medicines Initiative
ID : BTCure 115142
Pays : International
Organisme : FP7 Health
ID : FP7-HEALTH-F2-2012-305549
Pays : International
Organisme : ReumaNederland
ID : 11-1-308
Pays : International
Organisme : ReumaNederland
ID : 14-2-403
Pays : International
Organisme : Margareta af Ugglas Foundation
ID : not applicable
Pays : International
Références
Nat Commun. 2016 Aug 30;7:12614
pubmed: 27571776
J Autoimmun. 1999 Mar;12(2):121-9
pubmed: 10047432
Ann Intern Med. 1999 Mar 16;130(6):478-86
pubmed: 10075615
Arthritis Rheum. 2005 Nov;52(11):3433-8
pubmed: 16255021
Hum Immunol. 1994 Dec;41(4):285-91
pubmed: 7883596
Arthritis Res Ther. 2012 May 17;14(3):R118
pubmed: 22594821
Ann N Y Acad Sci. 2003 Nov;1005:82-7
pubmed: 14679042
J Virol. 2010 Apr;84(7):3312-9
pubmed: 20071564
Arthritis Rheum. 2013 Apr;65(4):899-910
pubmed: 23310951
J Exp Med. 1993 Jul 1;178(1):187-96
pubmed: 8315377
Arthritis Rheum. 2011 Oct;63(10):2873-83
pubmed: 21567378
Ann Rheum Dis. 2004 May;63(5):508-16
pubmed: 15082480
Cell Immunol. 1983 Oct 15;81(2):435-40
pubmed: 6196128
Cell Immunol. 2019 Jan;335:68-75
pubmed: 30428974
Science. 1996 Oct 4;274(5284):94-6
pubmed: 8810254
Arthritis Rheum. 1987 Nov;30(11):1205-13
pubmed: 2446635
Lancet. 2008 Mar 22;371(9617):987-97
pubmed: 18358926
J Rheumatol. 1998 Jan;25(1):16-22
pubmed: 9458197
J Clin Invest. 2002 Apr;109(7):895-903
pubmed: 11927616
J Immunol. 2008 Jun 1;180(11):7423-30
pubmed: 18490742
Proc Natl Acad Sci U S A. 2011 Oct 18;108(42):17372-7
pubmed: 21987802
J Autoimmun. 2018 Aug;92:47-56
pubmed: 29853344
J Clin Invest. 2003 Sep;112(6):831-42
pubmed: 12975468
J Allergy Clin Immunol. 2010 Jun;125(6):1407-1409.e1
pubmed: 20513526
Immunol Rev. 2010 Jan;233(1):34-54
pubmed: 20192991
J Clin Invest. 1998 Feb 15;101(4):746-54
pubmed: 9466968
Nature. 1999 Oct 14;401(6754):708-12
pubmed: 10537110
N Engl J Med. 2014 Jun 19;370(25):2377-86
pubmed: 24941177
Ann Rheum Dis. 2012 Nov;71(11):1911-2
pubmed: 22689316
Ann Rheum Dis. 2015 Feb;74(2):375-80
pubmed: 24276366
Immunity. 2009 Mar 20;30(3):324-35
pubmed: 19303387
Lancet. 2008 Oct 25;372(9648):1502-17
pubmed: 18970977
J Allergy Clin Immunol. 2012 Feb;129(2):544-51, 551.e1-7
pubmed: 21975176
Arthritis Rheum. 2011 Dec;63(12):3733-9
pubmed: 22094856
Clin Dev Immunol. 2012;2012:827480
pubmed: 22649468
J Clin Invest. 1999 Dec;104(12):R63-7
pubmed: 10606632
Arthritis Rheum. 2009 Aug;60(8):2272-83
pubmed: 19644849
J Immunol. 2004 May 15;172(10):5967-72
pubmed: 15128778
Nature. 2017 Feb 1;542(7639):110-114
pubmed: 28150777
Front Immunol. 2016 Nov 14;7:494
pubmed: 27895642
Diabetes. 2017 Dec;66(12):3051-3060
pubmed: 28842400
Arthritis Rheum. 1999 May;42(5):963-70
pubmed: 10323452
Arthritis Rheumatol. 2014 Jan;66(1):31-9
pubmed: 24449573
Curr Diab Rep. 2011 Dec;11(6):533-42
pubmed: 21912932
J Autoimmun. 1999 Sep;13(2):267-82
pubmed: 10479395
N Engl J Med. 2005 Sep 15;353(11):1114-23
pubmed: 16162882
Ann Rheum Dis. 2018 Feb;77(2):175-187
pubmed: 28765121
PLoS One. 2014 Nov 18;9(11):e112882
pubmed: 25405480
Cell Immunol. 2012;273(2):133-9
pubmed: 22270037
Proc Natl Acad Sci U S A. 2007 Feb 20;104(8):2831-6
pubmed: 17307878
J Neurosci Res. 1988;19(1):149-56
pubmed: 2449544
Front Immunol. 2018 Jan 22;9:8
pubmed: 29403492
Arthritis Rheum. 2006 Jan;54(1):38-46
pubmed: 16385494
Arthritis Rheumatol. 2014 Jul;66(7):1712-22
pubmed: 24665079
Arthritis Rheum. 2006 Sep;54(9):2793-806
pubmed: 16947627
Arthritis Rheum. 2008 Nov;58(11):3319-29
pubmed: 18975346
Br J Rheumatol. 1998 Jan;37(1):7-14
pubmed: 9487244
Nat Rev Immunol. 2018 Jun;18(6):363-373
pubmed: 29520044
Lancet. 1999 Dec 4;354(9194):1932-9
pubmed: 10622295
Arthritis Rheum. 2010 Jan;62(1):143-9
pubmed: 20039419
Nature. 1990 Sep 13;347(6289):151-6
pubmed: 1697648